Abstract 2391P
Background
Micropapillary urothelial carcinoma (MUC) is a rare and aggressive histological variant with poor clinical outcomes and limited consensus regarding its management. The mainstay of treatment in muscle-invasive disease is radical cystectomy (RC). Data regarding the role of neoadjuvant chemotherapy (NAC) and adjuvant chemotherapy (AC) in muscle-invasive MUC is limited.
Methods
The United States National Cancer Database was queried for patients (pts) with MUC diagnosed from 2004 to 2018. Pts older than 18 years with cT2-4aN0-1M0 MUC who underwent RC were included. Clinical T4b/N2-3/M1 and receipt of NAC+AC were used as exclusion criteria. The pts were divided into three cohorts based on perioperative therapy- NAC, AC, and no chemotherapy (CX-). Chi-Square and Kruskal-Wallis tests were used to compare frequency distributions. Cox Proportional Hazards regression was employed to adjust for confounders associated with overall survival (OS). Models were adjusted for age, race, sex, stage, insurance, and comorbidities.
Results
Of the 477 pts included, 80% were males, and 93% were White. 103 (21.6%) and 157 (32.9%) received NAC and AC, respectively, while 217 (45.5%) belonged to the CX- group. Pts in the NAC & AC groups were younger (66 yrs vs 73 yrs in CX-, p<0.001). OS was longer in the NAC and AC groups (Table). However, on multivariable analysis, NAC was predictive of OS (Hazard Ratio (HR) 0.68, 95% CI 0.47-0.97, p = 0.03) while AC was not (HR 0.84, 95% CI 0.63-1.12, p =0.22). In a separate Cox model, pT0-1N0 disease was independently associated with improved OS (HR 0.27, 95% CI 0.12-0.61, p=0.002). The NAC group had significantly more pT0N0 (14.8% vs 2.8%, p<0.001) & pT0-1N0 (21% vs 5.9%, p<0.001) disease at RC compared to the combined cohort of AC+CX-.
Table: 2391P
Cohort | Median OS (months) | 3-year OS (%) | 5-year OS (%) | Median follow-up (months) | Log-rank P |
CX- | 23.1 (18.1-28.7) | 40 (30-47) | 34 (27-41) | 68.7 | 0.008 |
AC | 34.0 (25.7-59.2) | 49 (40-57) | 40 (31-49) | 51.5 | |
NAC | 56.4 (30.1-NR) | 55 (43-65) | 45 (33-57) | 46.4 |
Conclusions
In this large retrospective analysis, NAC was independently predictive of longer OS in muscle-invasive MUC, while AC was not. NAC was also associated with pathological downstaging.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A.M. Roy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2393P - Ephrin signalling mediates resistance to programmed death ligand 1 (PD-L1) inhibition in urothelial carcinoma (UC)
Presenter: Yu-Hsuen Yang
Session: Poster session 24
2394P - Biomarkers of treatment (Tx)-related toxicity in advanced urothelial carcinoma (aUC) pts treated with enfortumab vedotin (EV): Analysis of UNITE study
Presenter: Amanda Nizam
Session: Poster session 24
2395P - Micropapillary histology (MPUC) and extra-cellular domain ERBB2 (ERBB2 ECD+) mutations in urothelial bladder cancer (UBC)
Presenter: Akshay Sood
Session: Poster session 24
2396P - Relationship of tumor fraction in circulating tumor DNA (ctDNA) with prognosis in patients with advanced urothelial cancer
Presenter: Benjamin Miron
Session: Poster session 24
2398P - Are fibroblast growth factor receptor 3 (FGFR3) alterations a possible predictive factor for platinum-based chemotherapy and immunotherapy in metastatic urothelial carcinoma (MUC)?
Presenter: Laura Ferrer-Mileo
Session: Poster session 24
2399P - Circulating tumor DNA and urine tumor DNA detection of minimal residual disease in upper tract urothelial carcinoma with radical nephroureterectomy: A cohort study
Presenter: Wei Xue
Session: Poster session 24
2400P - Frequency and nature of genomic alterations (GA) in ERBB2-altered urothelial bladder cancer (UBC)
Presenter: Rafee Talukder
Session: Poster session 24
2401P - Detection of molecular recurrence in early-stage bladder cancer patients using a urinary tumor DNA assay after transurethral resection of bladder tumor (TURBT)
Presenter: Ruiyun Zhang
Session: Poster session 24